Antares Pharma, Inc. (ATRS): Price and Financial Metrics
Antares Pharma, Inc. (ATRS)
Today's Latest Price: $3.12 USD
Updated Nov 27 1:00pm
Add ATRS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
ATRS Stock Summary
- Price to trailing twelve month operating cash flow for ATRS is currently 39.74, higher than 89.41% of US stocks with positive operating cash flow.
- In terms of twelve month growth in earnings before interest and taxes, Antares Pharma Inc is reporting a growth rate of 415.74%; that's higher than 96.37% of US stocks.
- As for revenue growth, note that ATRS's revenue has grown 36.68% over the past 12 months; that beats the revenue growth of 86.81% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Antares Pharma Inc are UEIC, SVM, SSTK, UCTT, and CARG.
- ATRS's SEC filings can be seen here. And to visit Antares Pharma Inc's official web site, go to www.antarespharma.com.
ATRS Stock Price Chart Interactive Chart >
ATRS Price/Volume Stats
| Current price | $3.12 | 52-week high | $5.13 |
| Prev. close | $3.03 | 52-week low | $1.60 |
| Day low | $2.98 | Volume | 618,000 |
| Day high | $3.13 | Avg. volume | 1,222,962 |
| 50-day MA | $2.96 | Dividend yield | N/A |
| 200-day MA | $2.83 | Market Cap | 520.02M |
Antares Pharma, Inc. (ATRS) Company Bio
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company was founded in 1979 and is based in Ewing, New Jersey.
ATRS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $3.12 | $0.01 | -100% |
We started the process of determining a valid price forecast for Antares Pharma Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Antares Pharma Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for ATRS, they are:
- The company's compound free cash flow growth rate over the past 0.5 years comes in at -0.5%; that's greater than only 2.24% of US stocks we're applying DCF forecasting to.
- As a business, Antares Pharma Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -100% |
| 1% | -100% |
| 2% | -100% |
| 3% | -100% |
| 4% | -100% |
| 5% | -100% |
Want more companies with a valuation profile/forecast similar to that of Antares Pharma Inc? See AGHC, ALC, AMRN, MOR, and PACB.
Loading social stream, please wait...